Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pagibaximab in VLBW Neonates for Prevention of Staphylococcal Infection
NCT00631800Phase 2Completed
- Sponsor
- Biosynexus Incorporated
- Start
- May 2003
- Primary completion
- Mar 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pagibaximab in staphylococcal infection (3 arms), sponsored by Biosynexus Incorporated. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started May 2003; status: completed.
02
Drugs
pagibaximab
03
Conditions
staphylococcal infection
Beyond the preview
Go deeper on NCT00631800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00631800.